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ABSTRACT  
Several studies on humans and mice support oxytocin’s role in improving social behaviour, but its 
use in pharmacotherapy presents some important limiting factors. To date, it is emerging a 
pharmacological potential for melanocortin 4 receptor (MC4R) agonism in social deficits treatment. 
Recently, we demonstrated that the deletion of the NFKB1 gene, which encodes the p50 NF-κB 
subunit, causes impairment in social behaviours, with reductions in social interactions in mice. In 
this work, we tested the acute effects of THIQ, a selective melanocortin 4 receptor (MC4R) agonist. 
THIQ treatment increased social interactions both in wild type and p50-/- mice. In particular, after 
treatment with THIQ, p50-/- mice showed a prosocial behaviour analogous to that of basal WT mice. 
Moreover, intranasal treatment with an oxytocin antagonist blocked social interactions induced by 
THIQ, demonstrating that its prosocial effects are mediated by the oxytocin pathway. The data 
obtained reinforce using MC4R agonists to ameliorate social impairment in NDDs. 
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1. Introduction 
Social interaction is a primary and adaptive behavioural component of mammalian species. For 
social animals, the interaction is important for the organization and stability of societies to define 
social hierarchy and for mate choice (Berry and Bronson, 1992). Several neurodevelopmental 
disorders (NDDs) such as schizophrenia and autism are characterized by social behavioural deficits. 
NDDs include developmental brain dysfunction characterized by neuropsychiatric deficits 
generating impairments in motor function, learning, verbal or non-verbal communication, social, or 
occupational functioning. All these phenotypic alterations have neuroanatomical basis. Indeed, 
increased cortical layers thickness, an abnormal columnar organization, cortex misconnections are 
often associated with NDDs (Innocenti et al., 2003; Budday et al., 2015). Recently, we observed 
specific neurodevelopmental alterations in a genetic mouse model, namely the NF-κB p50 knock 
out (p50 KO) mouse (Bonini et al., 2016). p50 KO mice were generated by targeted deletion of the 
NFKB1 gene that encodes for the precursor of the p50 NF-κB subunit. NF-κB is involved in many 
physiological functions such as immune and inflammatory responses, cell survival and death (Grilli 
and Memo, 1999; Kucharczak et al., 2003), in cell plasticity and morphology remodelling (Mattson, 
2005; Gutierrez and Davies, 2011; Bonini et al., 2011). This mouse model has been widely used in 
studies on inflammation, immunity, metabolic diseases and cancer (de Valle et al., 2016; Minegishi 
et al., 2015; Southern et al., 2012). Moreover, we found that adult p50 KO mice display abnormal 
columnar organization in the somatosensory cortex and altered neurite orientation, associated with 
hyperactivity and impairment in social behaviours with a reduction in social interactions (Bonini et 
al., 2016). All these cortical and behavioural alterations have also been reported in different NDD 
models, including models of autism spectrum disorders (ASD) and schizophrenia (Casanova et al., 
2006; Casanova et al., 2008; Beasley et al., 2009; Stoner et al., 2014, Gaudissard et al., 2017).  
Drugs currently used for NDDs are mainly symptomatic and often are ineffective for social deficits 
(Ji and Findling, 2016). Therapeutic intervention commonly aims to reduce psychotic symptoms 
and relies on atypical antipsychotics, especially risperidone, aripiprazole and olanzapine (Lamberti 
et al., 2016; Mastinu et al., 2012; Lazzari et al., 2017). No current medical treatments exist for 
prevention of NDDs and for amelioration of social deficits. Indeed, risperidone treatment in p50 KO 
mice resulted in decreased hyperactivity but had no effect on social deficits (Bonini et al., 2016). A 
promising compound to rescue social impairments in NDDs is represented by oxytocin (Woolley et 
al., 2015; Gordon et al., 2013; Kirsch 2015). Oxytocin is synthesized in the neurons of the 
paraventricular nuclei (PVN) and supraoptic nuclei (SON) of the hypothalamus and released in the 
brain or in the blood (Ludwig and Leng, 2006). Oxytocin exerts several neuroendocrine functions 
when released in the peripheral bloodstream and modulates social behaviour when released in the 
brain. In particular, oxytocin has been reported to increase social stimuli, to promote parental 
nurturing and social bonds in mouse models of ASD (Peñagarikano et al., 2015; Teng et al., 2016). 
Furthermore, intranasal oxytocin improved social deficits both in patients 
with schizophrenia/schizoaffective disorder (Shilling and Feifel, 2016) and in ASD patients (Andari 
et al., 2010; Guastella et al., 2010). Studies in humans support the pharmacological role of oxytocin 
in stress, anxiety disorders, social phobia, postpartum depression, and bipolar disorder, with a 
positive action on reward in social behaviour and communication (MacDonald et al., 2013; Singer 
et al., 2008). Lastly, oxytocin is involved also in peripheral inflammatory responses mediated by 
NF-κB, as previously reported (Soloff et al., 2006; Kim et al., 2015). In particular, Soloff and 
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colleagues hypothesize that the NF-κB p65 subunit interacts with the promoter of the oxytocin 
receptor and down regulates its expression. At present the specific mechanisms of p65 interaction 
with the oxytocin receptor promoter remains considerably complex.  
Despite these encouraging results both in animal models and in humans, the use of oxytocin in 
pharmacotherapy presents some relevant limitations. First of all, oxytocin is a peptide therefore it 
cannot be used by oral administration. Another adverse factor is represented by oxytocin’s short 
half-life. Indeed, oxytocin degrades very rapidly by intravenous administration, resulting in short-
lasting effects (Modi et al., 2016). Furthermore, its brain penetrance is uncertain; indeed, some 
studies report that only a small fraction can pass the blood brain barrier and enter the brain (Mens et 
al., 1983; Guastella et al., 2013). On the contrary, Lee and colleagues demonstrated cerebrospinal 
fluid penetrance of exogenous oxytocin administered peripherally, by intranasal or intravenous 
route (Lee et al., 2017). Intranasal delivery resulted to be the more efficient pathway for oxytocin 
compared to intravenous administration, but unfortunately it presented wide variability of both 
cerebrospinal fluid and plasma concentrations between different treated animals (Lee et al., 2017). 
Hence, it is not a manageable treatment.  
To circumvent these problems, compounds able to enhance endogenous oxytocin release can be 
used. Sabatier et al. (2003) showed that α melanocyte-stimulating hormone (αMSH) has a selective 
modulatory action on SON oxytocin neurons via melanocortin 4 receptor (MC4R) agonism. 
Moreover, MC4R agonist treatment increases oxytocin release in the brain (Sabatier et al., 2003) 
and promotes partner preference in voles (Modi et al., 2015). THIQ is a selective and potent MC4R 
agonist; it is an orally active small non-peptide MC4R mimetic compound (Grunewald et al., 1999). 
In addition, THIQ can penetrate the blood-brain barrier (BBB), as previously reported by an in vitro 
BBB permeability study (Grunewald et al., 1999). Moreover, it shows chemical properties of log P 
5.65 ± 0.93, calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02. 
THIQ has already been reported to induce MC4R-mediated erectogenic effects in both mice and 
rats with sexual dysfunctions (Martin et al., 2002). 
To identify a correlation between social deficit and the oxytocin pathway in p50 KO mice, we 
initially measured the oxytocinergic tone. Then, we evaluated the THIQ effect on social deficits and 
whether this effect was mediated by oxytocin pathway.  
 
2. Materials and Methods 
2.1. Animals  
Experiments were conducted in conformity with the European Communities Council Directive of 
1986 (86/609/EEC), approved by the Italian Ministry of Health, and the Animal Care and Use 
Committee of the University of Brescia. Animals were housed two-to-three per cage in a 12 hours 
light/dark cycle (light phase from 8:00 a.m. to 8:00 p.m.) with food and water available ad libitum. 
The cage size was 15 cm wide x 35 cm long x 12 cm deep. Temperature (22 °C) and humidity (50% 
± 10) in the cages were automatically regulated by the Sealsafe Aero System by individually 
ventilated cages with EPA filters (Tecniplast Group, Italy). NF-κB p50-/- mice (B6;129P2-Nfkb 1tm 
1 Bal/J) and wild-type mice (B6;129PF2) were purchased from The Jackson Laboratories (Bar 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Harbor, ME, USA). Stable mating couples were maintained to amplify the colony and the progeny 
was used for the experiments. In particular, wild-type (WT) and p50-/- (p50 KO) age-matched mice 
(4-6-month-old mice; weight = 25-35 g) were used. All the experiments were performed on male 
mice.  
 
2.2. Drugs and pharmacological treatment 
For pharmacological treatment, melanocortin 4 receptor agonist THIQ (N-[(1R)-1-[(4-
Chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-trazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-
1,2,3,4-tetrahydro-3-isoquinolinecarboxamide, Tocris Bioscience, Bristol, UK) was administered 
acutely via intraperitoneal injection 30 min before the behavioural tests, according to previously 
reported data (Peñagarikano et al., 2015). THIQ doses were 0.5, 1, and 2 mg/kg in a 10 ml/kg 
volume, 250 µl for an average 25 g mouse and were chosen on the basis of previous data reporting 
Ki, IC50 and MC4R activation (Martin et al., 2002; Sebhat et al., 2002). Oxytocin receptor 
antagonist, L-371,257 (Tocris Bioscience, Bristol, UK) was intranasally administered at a dose of 
300 µg/kg; a drop of a 2.5 µL solution was placed in the animal nostril with a P10 pipette to induce 
the mouse to aspirate the drop into its nasal cavity. The mice received L-371,257 15 min before 
THIQ administration (Peñagarikano et al., 2015). All drugs, suspended in 0.9% saline solution, 
were prepared daily, sonicated, and administered.  
 
2.3. Radioimmunoassay 
To correlate oxytocin levels with THIQ treatment, we measured hypothalamic oxytocin levels 30 
min after intraperitoneal drug administration as reported previously (Peñagarikano et al., 2015). 
Mice (6 for WT and 5 for the p50 KO mice group) were sacrificed and hypothalamus was isolated, 
weighted and homogenized with acetic acid (Sigma Aldrich, Milano, Italy) 50% v/v. Then, the 
tissue homogenate was boiled for 10 minutes at 100 °C and centrifuged at 12000 rpm for 30 
minutes at 4 °C. One mL of supernatant was combined with 1 mL of Buffer A (Phoenix 
Pharmaceuticals, Burlingame, CA, USA) and centrifuged at 12000 x g for 20 minutes, and we 
collected the supernatant. After, the samples were extracted onto the C-18 sep column (Phoenix 
Pharmaceuticals, Burlingame, CA, USA). The eluted sample was frozen at least three hours before 
being placed in the lyophilizer. The lyophilized sample was reconstituted with one x assay buffer 
for RIA detection (Phoenix Pharmaceuticals, Burlingame, CA, USA). Briefly, the standard peptide, 
the antibody, the positive control, and unknown samples were reconstituted, and RIA buffer was 
diluted with 150 mL of distilled water. Dilutions of the standard peptide and samples were prepared 
and incubated at 4 °C for 16 or 24 hours. Subsequently, the 125I-peptide was added and all tubes 
were incubated for another 16 or 24 hours at 4 °C. After the addition of antibody, all tubes were 
incubated at room temperature, centrifuged and a γ-counter was used to count the cpm (counts per 
minute) of the pellet. 
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2.4. qRT PCR 
Total RNA was isolated from hypothalamic tissue and dissected from WT and p50 KO mice brain. 
To purify RNA, the RNeasy kit (Qiagen, Milano, IT) was used and RNA was digested with the 
RNase Free DNase set (Qiagen, Milano, IT), according to the manufacturer’s protocol. RNA quality 
of samples was tested by RNA electrophoresis to ensure RNA integrity. RNA was quantified by 
means of mySpec spectrophotometer (VWR, Milano, IT). One micrograms of total RNA from WT 
and KO hypothalamic tissue was transcribed into cDNA using murine leukemia virus reverse 
transcriptase (Promega, Milano, IT) and oligo(dT) 15–18 as a primer (final volume: 50 uL). Parallel 
reactions containing no reverse transcriptase were used as negative controls to confirm the removal 
of all genomic DNA. The following murine-specific primers, previously reported in the literature 
(Gutkowska et al., 2009), were used: oxytocin forward primer 5’-CCT ACA GCG GAT CTC AGA 
CTG A-3’, reverse primer 5’- TCA GAG CCA GTA AGC CAA GCA-3’, oxytocin receptor 
forward primer 5’-CGA CTC AGG ACG AAG GTG GAG GA-3’, and reverse primer 5’-AAG 
ATG ACC TTC ATC ATT GTT C-3’. Amplification and detection were performed with the ViiA7 
Real Time PCR Detection System (Applied Biosystem, Monza, IT); the fluorescence signal was 
generated by SYBR Green I. Samples were run in triplicate in a 12 µL reaction mix containing 6 µL 
of 2×SYBR Green Master Mix (BIO-RAD Laboratories, Segrate, IT), 6 pmol of each forward and 
reverse primer, and 2 µL of diluted cDNA. The SYBR Green Master Mix includes ROX for passive 
reference. Each PCR experiment included serial dilutions of a positive control for the construction 
of the calibration curve, a positive and a negative DNA sample, and water blanks. The PCR 
program was initiated by 10 min at 95 °C before 40 cycles, each one of 1 s at 95 °C and 30 sec at 64 
°C. A subsequent dissociation curve analysis verified the product’s specificity. Gene expression 
levels were normalized to β Actin expression (forward primer: 5'-AGC CAT GTA CGT AGC CAT 
CC-3', reverse primer: 5'-CTC TCA GCT GTG GTG GTG AA-3’) and data are presented as the 
fold change in target gene expression in p50 KO mice hypothalamic tissue normalized to the 
internal control gene and relative to WT mice hypothalamic tissue. The results were estimated as Ct 
values; the Ct was calculated as the mean of the Ct for the target gene minus the mean of the Ct for 
the internal control gene. The Ct represented the mean difference between the Ct of p50 KO minus 
the Ct of WT mice hypothalamic tissue. The N-fold differential expression in the target gene of p50 
KO compared to WT mice hypothalamic tissue was expressed as 2-∆∆Ct. Data analysis and graphics 
were performed using GraphPad Prism 5 software and results were obtained employing 7-8 mice 
per group (WT and p50 KO hypothalamic tissue), and each sample was run in triplicate for each 
gene. 
 
2.5. Reciprocal social interactions  
Fine-grained measures of interactions between pairs of adult mice placed together in standard cages 
or arenas provide the most detailed insights into reciprocal social interactions (Silverman et al., 
2010). For this behavioural analysis, 6-8 pairs of 4 to 6-month-old male age-matched mice for each 
genotype were used and a modified version of the Silverman protocol was applied. In particular, 
experimental mice were individually housed during 5 days preceding the behavioural test. Both 
mice in the pair were treated either with the same drug or with vehicle and used for the test. After a 
period of acclimation of 10 min into their cage in a quiet and dim experimental room, subjects were 
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exposed to an age, sex and strain matched unfamiliar subject (intruder subject) for 10 min. The 10 
min social test was video recorded and later analysed by two independent observers on the video 
collected with the IC Capture software (Vision Link, Bremen, DE). Duration of social activities 
(that include first contact latency, anogenital sniffing, nose to nose sniffing, wrestling, following, 
mounting, and pushing past each other with physical contact) and non social activities (cage 
exploring, self-grooming, and climbing) were measured. During the test, the operator remained in 
an adjacent room, separated with a dark sliding door from the test room. Specific behaviours 
observed during the social test belong to well-defined ethograms used to analyse social interaction 
in laboratory mice (Grant and Mackintosh, 1962; Rodriguiz et al., 2011). Separate values were 
obtained for each individual in a pair, but since the two values cannot be considered statistically 
independent, pair means were used for statistical analysis.  
 
2.6. Open Field 
The open field test was performed on new batches of mice. After being acclimated to the procedure 
room for at least 10 min, each of WT and p50 KO mice (age-matched adult littermates, 4-6 month 
old, 6-8 mice/group) was individually videotaped during a 5-min exploration session in a 40 cm × 
40 cm Plexiglas open field activity box. Mice were placed in the center of the arena at the beginning 
of the test period. Their movement around the arena was recorded by a portable video camera 
vertically mounted 1.5 meters above and remotely controlled by the experimenter. The Plexiglas 
box was cleaned after each individual test session to prevent subsequent mice from being influenced 
by odors deposited by previous mice. Testing was performed under normal room lights, during the 
light phase of the circadian cycle, between 09:30 and 17:30 h. Locomotor activity was recorded and 
total distance travelled, average speed and total time mobile were analysed and automatically scored 
with ANY-maze software. 
 
2.7. Statistical analysis 
Unpaired t test with Welch's correction was used for RIA experiments in basal conditions (WT 
versus p50 KO mice). Multiple t test corrected for multiple comparison using Holm-Šidák method 
was used real time PCR experiments. After the treatments, analysis of variance (ANOVA) with two 
levels of genotype and four levels of treatment as between group factors have been performed. In 
particular, two-way ANOVA with Šidák multiple comparison tests was performed for RIA, open 
field and social interaction test. Statistical analyses were performed by GraphPad Prism 5 software. 
Data are presented as the means ± S.E.M, with the statistical significance level set at p<0.05. 
 
3. Results 
3.1. Oxytocin pathway in hypothalamus of p50 KO and WT mice 
3.1.1. Oxytocin and oxytocin receptor 
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The OXT gene synthesizes an inactive precursor protein in the SON and PVN that includes the 
oxytocin carrier protein neurophysin I (Grinevich et al., 2015). Oxytocin, stored in vesicles, is 
released by axon terminals into the blood from the pituitary gland (Ludwig and Leng 2006). 
Moreover, the axon terminals show several connections with the mesolimbic area (including 
nucleus accumbens) that modulates the reward for social behaviour (Dumais and Veenema, 2016; 
Love, 2014). Here, first we analysed the levels of both oxytocin precursor and oxytocin receptor 
mRNA in WT and p50 KO mice. mRNA was obtained from hypothalamic tissue and 
retrotranscribed to cDNA; then, specific primers for oxytocin and oxytocin receptor were used for 
the qRT-PCR experiments. From this analysis emerged that both oxytocin and oxytocin receptor 
mRNA are significantly lower in p50 KO compared to WT mice (Fig. 1) (oxytocin, tratio = 2.56, df = 
12.0, p<0.05; oxytocin receptor, tratio = 2.84, df = 13.0, p<0.05). To quantify the neuropeptide 
content we also measured oxytocin levels in hypothalamus of p50 KO and WT mice by RIA. We 
quantified oxytocin from hypothalamus-extracted samples. Sample extraction is a technique to 
remove the effect of potentially interfering molecules, useful to concentrate and enrich the analyte 
of interest (Szeto et al., 2011). It is still matter of debate the importance of sample extraction before 
oxytocin quantification. Several groups measured oxytocin levels from “non extracted samples” 
(Schneiderman et al., 2012, Feldman et al., 2012, Weisman et al., 2012) and this generated 
heterogeneous results compared to results obtained with different oxytocin quantification protocols 
(McCullough et al., 2013, Leng and Ludwig 2015, Leng and Sabatier 2016). According to Leng and 
Sabatier, that reported the importance of extraction to eliminate interfering factors, we decided to 
extract the samples. In line with qRT-PCR results, basal hypothalamic oxytocin levels were 
significantly lower in p50 KO compared to WT mice by RIA quantification (t = 4.3, df = 4.4, 
p<0.05, Figure 2A), suggesting a hypothalamic decrease in oxytocin activity based on reduced 
expression of neurohormone.  
 
3.2. THIQ effect in WT and p50 KO mice   
3.2.1. Oxytocin detection after THIQ treatment by RIA 
Previous data showed that MC4R agonists improve the central oxytocinergic tone (Sabatier et al. 
2003). In the present study, an acute treatment with THIQ, a MC4R agonist, was executed, and the 
neuropeptide content in the total hypothalamus was quantified by RIA 30 min after drug injection 
(Peñagarikano et al., 2015). THIQ treatment induced an increase in oxytocin level in WT and p50 
KO mice (Finteraction (3, 36) = 0.46, p=0.71; Ftreatment (3, 36) = 10.68, p<0.0001; Fgenotype (1, 36) = 
3.48, p=0.07; Figure 2B).  These data confirm an interaction between the oxytocin and 
melanocortin pathways and suggest a THIQ-dependent increase in oxytocin transit from the SON 
and PVN to the pituitary gland or other areas of the brain.  
 
3.2.2. Behavioural effects after THIQ treatment    
p50 KO mice are characterized by specific behavioural impairments, including hyperactivity and 
increased exploratory attitude (Bonini et al., 2016, Denis-Donini et al., 2008), reduced social 
interactions (Bonini et al., 2016) and decreased tendency to establish dominant subordinate 
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relationships among cage mates (Kassed et al., 2004). To modify or even revert some of these 
deficits and demonstrate the central role of MC4R agonism in increasing the oxytocinergic 
response, WT and p50 KO mice were acutely treated with 0.5, 1, or 2 mg/kg THIQ (i.p.) and tested 
in the reciprocal social interaction paradigm and in the open field test 30 minutes after drug 
administration. To better clarify the sort of social behaviour performed, a more detailed analysis of 
the different behaviours has been done. Social behaviours have been classified as follow: “social 
investigation”, that include first contact latency, nose to nose sniffing, body sniffing, nose to 
anogenital sniffing, following, and “aggressive behaviours”, that include wrestling, mounting and 
pushing past each other with physical contact. Since mice analysed spent minimal time in 
aggressive behaviours and no significant difference emerged between groups, only social 
investigation activities were reported in the graph. Regarding basal behaviours, as expected and 
shown in Figure 3A, p50 KO mice spent significantly less time (expressed in seconds) in social 
activities compared to WT mice. Conversely, p50 KO mice spent more time in non-social activities 
compared to WT mice (Figure 3B). Interestingly, treatment with THIQ significantly increased 
social attitude both in WT and in p50 KO mice at all the doses used [(Social investigation: Finteraction 
(3, 56) = 1.37, p=0.26; Ftreatment (3, 56) = 16.87, p<0.0001; Fgenotype (1, 56) = 41.25, p<0.0001); 
(Aggressive behaviours: Finteraction (3, 56) = 1.37, p=0.26; Ftreatment (3, 56) = 0.18, p=0.91; Fgenotype (1, 
56) = 0.25, p=0.62); Figure 3A]. Concerning non social activity, the time spent in these actions was 
significantly decreased in THIQ-treated WT and p50 KO mice [(Non social behaviours: Finteraction 
(3, 56) = 1.59, p=0.201; Ftreatment (3, 56) = 18.5, p<0.0001; Fgenotype (1, 56) = 43.06, p<0.0001); 
Figure 3B]. In both WT and p50 KO mice THIQ provoked a significant decrease in time spent 
doing exploring compared to vehicle treated mice. It is noteworthy that THIQ treatment did induce 
in both WT and KO mice an increase in time spent doing social interaction without affecting 
“aggressive behaviour”. 
Finally, we investigated the mice locomotor and exploratory activity by the open field test. We 
confirmed the increased motor activity of p50 KO mice compared to WT; indeed, p50 KO mice 
presented an increase in distance travelled and in walking speed compared to WT mice [(Distance 
travelled: Finteraction (3, 45) = 1.23, p=0.31; Ftreatment (3, 45) = 0.93, p=0.43; Fgenotype (1, 45) = 13.53, 
p=0.0006); (Speed: Finteraction (3, 45) = 1.37, p=0.26; Ftreatment (3, 45) = 1.01, p=0.4; Fgenotype (1, 45) = 
12.0, p=0.001); (Total time mobile: Finteraction (3, 45) = 2.86, p=0.05; Ftreatment (3, 45) = 1.98, p=0.13; 
Fgenotype (1, 45) = 3.01, p=0.09); Figure 4]. THIQ treatment did not manifest any significant effect 
on exploratory behaviour and motility in both WT and p50 KO mice. Finally, we performed a 
separate ANOVA in each dose with genotype as a between subject factor but it did not reveal any 
significant difference. These results suggest that THIQ treatment has a direct effect on social 
interaction in p50 KO mice without affecting “aggressive behaviours” or locomotor activity. 
 
 
3.3. Prosocial effect is mediated by the oxytocin pathway 
To establish if the THIQ prosocial effect was mediated by oxytocin, we took advantage of the 
availability of an oxytocin antagonist. The compound L-371,257 was administered at the dose of 
300 µg/kg via intranasal administration 15 min before THIQ treatment. For THIQ we used the 0.5 
mg/kg dose. As shown in Figure 5A, the antagonist alone did not generate a behavioural response 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
both in WT and p50 KO mice. On the contrary, when mice were cotreated with L-371,257 and 
THIQ, the prosocial effect of the MC4R agonist was blocked both in WT and p50 KO mice [(Social 
investigation: Finteraction (3, 62) = 0.83, p=0.48; Ftreatment (3, 62) = 14.79, p<0.0001; Fgenotype (1, 62) = 
33.44, p<0.0001); (Aggressive behaviours: Finteraction (3, 62) = 1.97, p=0.13; Ftreatment (3, 62) = 0.74, 
p=0.53; Fgenotype (1, 62) = 0.502, p=0.48); Figure 5A]. In addition, WT and p50 KO mice spent more 
time in exploration and non social activities when treated with L-371,257-THIQ compared to THIQ 
only [Non social behaviours: Finteraction (3, 62) = 0.96, p=0.42; Ftreatment (3, 62) = 14.15, p<0.0001; 
Fgenotype (1, 62) = 30.24, p<0.0001); Figure 5B]. Based on these results, acutely administered THIQ 
stimulates social interactions, but this behavioural effect is eliminated when the oxytocin receptor is 
blocked by L-371,257. Data obtained suggest that the THIQ prosocial effect is mediated by 
oxytocin pathway. 
 
4. Discussion 
In this work, we studied the effect of an acute treatment with THIQ, a selective melanocortin 
receptor agonist, on social behaviour and measured oxytocinergic tone in WT and p50 KO mice. In 
vertebrates, the oxytocin system innervates brain networks that modulate social behaviour and 
generates attitudinal trust (Kent et al., 2016, Nishina et al., 2016). Oxytocin has been proven to 
modulate the processing of social cues in a prosocial direction by increasing the reward value of 
positive social cues while buffering against experiences of negative emotionality in healthy subjects 
(Kanat et al., 2014). It emerged as a potent modulator of diverse aspects of interpersonal 
relationships (Patin et al., 2017). Interestingly, more than twenty years ago, a link between the 
oxytocin pathway and autism spectrum disorders (ASD) emerged. Indeed, several studies revealed a 
deficit of oxytocin/oxytocin receptor in ASD patients brain (Jacob et al., 2007; Gregory et al., 2009) 
and low plasma oxytocin levels (Modahl et al., 1998; Andari et al., 2010). Surprisingly, a single 
intranasal dose of oxytocin was able to improve social performance (Andari et al., 2010; Guastella 
et al., 2010).  
We previously demonstrated that p50 KO mice exhibit behavioural impairments such as 
hyperactivity, increased locomotor and exploratory activities, and reduced social interactions 
(Bonini et al., 2016). Considering behavioural alterations found in p50 KO mice, we asked if 
hypothalamic oxytocin pathway could be involved in p50 KO mice behaviour impairments.  
First, we found lower mRNA levels of both oxytocin precursor and oxytocin receptor in the 
hypothalamus of p50 KO when compared to WT mice. In this regard, it has been demonstrated that 
p65 NF-κB subunit interacts with the oxytocin pathway and modulates its expression (Soloff et al., 
2006; Kim et al., 2015). Moreover, we previously evaluated p65 protein levels in p50 KO neuronal 
cortical cells and we found that p50 KO expressed significantly higher protein levels (+152%) 
compared with WT neurons (Bonini et al., 2011). Therefore, we hypothesize that the low expression 
of oxytocin pathway components could be associated to NF-κB pathway alteration. 
Central oxytocin is released both axonally and somatodendritically from the magnocellular and 
parvocellular neurons in the PVN and in mesolimbic area such as ventral tegmental area and 
nucleus accumbens (Peris et al., 2017). In particular, the mesolimbic area acts as reinforcement for 
many behavioural responses, including social interactions (Salamone and Correa, 2012). The 
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reduced expression of hypothalamic oxytocin and oxytocin receptor could lead to a decreased 
mesolimbic response that could explain the poor social behaviour in the p50 KO compared to WT 
mice. Furthermore, we cannot rule out that the reduced sociality of p50 KO mice generates a down 
regulation of the oxytocin. Indeed, the same social interaction increases the release of oxytocin, 
therefore p50 KO mice might have a social deficit which could lead to oxytocin down-regulation. 
These findings are consistent with previous studies showing that the oxytocin pathway modulates 
prosocial behaviours and that deficits in the oxytocin system generate sociability impairments 
(Kirsch, 2015). Furthermore, several mouse models of neurodevelopmental disorders present an 
oxytocin and/or oxytocin receptor dysregulation (Rich, 2015). Finally, some drug treatments with 
oxytocin have been performed both in murine models and/or humans to ameliorate social 
impairments, but ambiguous results were obtained. Indeed, despite the central role of the oxytocin 
system in prosocial behaviour and promising results obtained with oxytocin by intranasal treatment, 
its clinical use presents some important limitations. In particular, only a minimal amount of the 
huge quantity of oxytocin applied intranasally reaches the cerebrospinal fluid; on the contrary, 
intranasal application produce large and prolonged increases in circulating oxytocin, that can trigger 
actions on reproductive organs, the heart, and gastrointestinal tract (Leng and Ludwig, 2016). 
Furthermore, intranasal oxytocin administration present wide variability of response between 
individuals, and this can be due to variations in anatomy and resultant airflow dynamic, 
vascularisation, status of blood vessels, mode of spray application, etc. (Guastella et al., 2012). For 
this reason we focused our attention on a small non-peptide molecule with high affinity and 
selectivity for the melanocortin 4 receptor (MC4R), THIQ (Wikberg and Mutulis, 2008). MC4R is 
known to play a central role in food intake and energy expenditure (Krashes et al., 2016). Moreover, 
several studies demonstrated the involvement of MC4R also in neuroinflammation and sexual 
activity (Muceniece et al., 2007; Lansdell et al., 2010). Recently, Modi and colleagues have found a 
link between MC4R activation and behaviours of partner preference associated with the oxytocin 
pathway in prairie voles (Modi et al., 2015). Indeed, MC4R activation interacts with several 
mesolimbic pathways such as oxytocin, dopamine and serotonin that modulate behaviours 
connected to reward, as mentioned above (Roseberry et al., 2015). Melanocortin agonism was 
reported to increase prosocial activity and to induce oxytocin release in the brain (Sabatier et al., 
2003). More specifically, MC4R agonists were shown to induce substantial release of oxytocin 
from dendrites in isolated hypothalamic supraoptic nuclei (Sabatier et al., 2003). Our results 
demonstrated how, after THIQ treatment, oxytocin in both WT and p50 KO mice is significantly 
increased over basal values at all tested doses. Hence, we suggest a direct role for THIQ in 
increasing oxytocinergic tone by stimulating oxytocin release.  
Our behavioural tests showed that 0.5 mg/kg THIQ acute treatment is able to improve social 
interactions between unfamiliar p50 KO mice. These findings are consistent with previous data 
showing that animals treated with melanocortin agonists exhibit more prosocial behaviours 
compared to control group (Peñagarikano et al., 2015; Modi et al., 2015). Indeed, we observed a 
strong prosocial effect also in WT mice treated with THIQ compared to basal WT mice.  
Although the prosocial response of MC4R agonists could be explained by an oxytocinergic tone 
improvement, some mechanisms need to be better defined. In fact, some authors did not observe 
changes in the oxytocin content in microdialysated samples collected in the somatosensory 
hypothalamic area after treatment with αMSH analogues in rats (Paiva et al., 2016). Moreover, 
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although Modi and colleagues hypothesized that melanotan II (αMSH analogue) could increase 
hypothalamic concentration of oxytocin and its release in mesolimbic area, they failed to prove it 
experimentally in female prairie voles (Modi et al., 2015). On the other hand, Peñagarikano and 
colleagues (2015) reported a social improvement and an endogenous oxytocin release after MC4R 
agonist in an ASD mouse model. From our results on behaviour and RIA, we hypothesize that acute 
THIQ treatment could increase hypothalamic oxytocin level, affecting social behaviour in p50 KO 
mice that become more prone to socialize. The results obtained cotreating mice with the oxytocin 
receptor antagonist L-371,257 could validate this hypothesis. Indeed, L-371,257 blocked the 
prosocial action of 0.5 mg/kg THIQ both in WT and in p50 KO mice during behavioural testing. 
Moreover, mice treated with the oxytocin antagonist showed a social behaviour equal to that 
observed in basal groups. Overall, these results can contribute to better defining MC4R agonist’s 
role in the regulation of social behaviour through oxytocin action.  
In conclusion, data obtained in this study demonstrated that p50 KO mice present an oxytocin 
pathway down regulation in the hypothalamus compared to WT mice. Moreover, THIQ treatment 
significantly increases social interactions both in WT and p50 KO mice, and this effect could be 
mediated by oxytocin since it is counteracted by an oxytocin receptor antagonist. At present, the 
mechanism by which THIQ affects oxytocin pathway requires further insights. Our results 
corroborate once again an important role for MC4R in social oxytocin-mediated behaviour. 
Moreover, future studies will be needed to better demonstrate the central role of MCR4 agonism to 
improve social deficits through the oxytocin pathway.   
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Figure Captions  
Fig. 1. mRNA expression of oxytocin and oxytocin receptor in the hypothalamus of WT and p50 KO mice. 
Both oxytocin (OXY) and oxytocin receptor (OXY-R) transcripts were significantly lower in p50 KO 
compared to WT mice (*p<0.05). Multiple t test analysis and statistical significance determined using the 
Holm-Sidak method. Data are expressed as the mean ± S.E.M. and relative quantification of target gene was 
expressed as 2-∆∆Ct. Target gene expression was normalized to β-actin expression. 
Fig. 2. Oxytocin detection in WT and p50 KO hypothalamus by RIA. Under basal conditions, hypothalamic 
oxytocin levels were significantly lower in p50 KO compared to WT mice (A). §§p<0.05 vs WT mice. Data 
are expressed as the mean ± S.E.M. Unpaired t test with Welch’s correction was done. After THIQ 
administration, an oxytocin increase in both WT and KO mice was observed (B). **p<0.01 vs WT VH, 
***p<0.001 vs WT VH, #p<0.05 vs KO VH. Data are expressed as the mean ± S.E.M. Two-way ANOVA 
followed by the Sidak's multiple comparisons test was executed. 
Fig. 3.  Effect of THIQ treatment on social behaviour in WT and p50 KO mice by the reciprocal social 
interaction test. The experimental mice were individually housed during the 5 days preceding the behavioural 
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test. Both mice in the pair were treated either with the same drug or with vehicle and used for a 10-min social 
test. (A) Social investigation includes first contact latency, nose-nose sniffing, ano-genital sniffing, body 
sniffing and following. (B) The following non social activities were evaluated: exploring and self-grooming. 
*p<0.05 vs WT VH, **p<0.005 vs WT VH, ##p<0.005 vs KO VH, ###p<0.0005 vs KO VH, ####p<0.0001 
vs KO VH, §§§p<0.0005 vs WT VH. Data are expressed as mean ± S.E.M. Two-way ANOVA followed by 
the Šidák’s multiple comparisons test was executed. 
Fig. 4. Effect of THIQ treatment on WT and p50 KO mice motility by Open Field Test. Graphic 
representation of data collected in the open field test by automatically measuring the total distance travelled 
(A), the speed (B) and the total time mobile (C). Data confirmed a higher exploratory behaviour and 
locomotor activity in p50 knock out (KO) compared to wild type (WT) mice treated with vehicle (VH). 
**p<0.01 by two-way ANOVA followed by the Šidák’s multiple comparison test. 
Fig. 5. Effects of L-371,257 treatment on social behaviour of WT and p50 KO mice. The compound L-
371,257 was administered at a dose of 300 µg/kg via intranasal administration 15 min before THIQ 
treatment; subsequently, social interaction testing was executed. Duration of social activities (A) and non 
social activities (B) were measured. (A) Social investigation includes first contact latency, nose-nose 
sniffing, ano-genital sniffing, body sniffing and following. (B) The following non social activities were 
evaluated: exploring and self-grooming. *p<0.05 vs WT VH, **p<0.005 vs WT VH, °°°p<0.0005 vs THIQ 
WT, °°°°p<0.0001 vs THIQ WT, #p<0.05 vs KO VH, &p<0.05 vs THIQ KO, &&p<0.005 vs THIQ KO, 
£££p<0.001 vs WT VH. Data are expressed as the mean ± S.E.M. Two-way ANOVA followed by the 
Šidák’s multiple comparisons test was executed. 
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Highlights: 
 p50 KO mice display poor social behavior, with a reduction in social interaction 
 p50 KO mice present both oxytocin and oxytocin receptor mRNA levels down-regulation 
 MC4-R agonist THIQ is able to improve social interaction between unfamiliar p50 KO mice 
 THIQ prosocial effects are mediated by oxytocin pathway 
 
 
